Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Overview 9 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 16 Products under Development by Universities/Institutes 22 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment 24 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30 Array BioPharma Inc 30 Astellas Pharma Inc 30 AstraZeneca Plc 31 Daiichi Sankyo Co Ltd 31 Dompe Farmaceutici SpA 32 Genzyme Corp 32 Handok Inc 33 Ignyta Inc 33 Loxo Oncology Inc 34 Merck & Co Inc 35 Nerviano Medical Sciences Srl 36 Plexxikon Inc 36 Proximagen Ltd 37 Rottapharm Biotech Srl 37 Sienna Biopharmaceuticals Inc 38 Tiziana Life Sciences Plc 38 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles 40 ACD-855 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 AR-523 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ARRY-954 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ASP-7962 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 AZD-7451 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 BNN-27 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 cenegermin - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 CRB-0089 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 DS-6051 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 entrectinib - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 GZ-389988 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 larotrectinib - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 milciclib - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 NMSP-626 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 NOV-1601 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 PLX-7486 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Small Molecule to Inhibit TrkA for Inflammatory Pain - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Small Molecules to Agonize TrkA and TrkB for Alzheimer’s Disease - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Small Molecules to Inhibit TRK1 for Pain - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 SNA-120 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 SNA-125 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Products 86 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products 89 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Product Development Milestones 91 Featured News & Press Releases 91 Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120 91 Oct 19, 2017: AlzeCure to Present Data on NeuroRestore Project at 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD) 92 Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset 92 Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors 93 Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer 93 Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer 94 Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer 95 Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress 96 Sep 07, 2017: Ignyta To Host Conference Call And Live Webcast On September 11 To Provide Pipeline Review, Including Lead Candidate Entrectinib 96 Sep 06, 2017: Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program 96 Aug 31, 2017: Daiichi Sankyo to Present Data on Tumor Drug Candidate DS-6051 at the European Society for Medical Oncology 2017 Congress 97 Aug 30, 2017: Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017 98 Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy 98 Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma 99 Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorisation For OXERVATE 100 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102

List of Tables Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15 Number of Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 17 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21 Number of Products under Investigation by Universities/Institutes, H2 2017 22 Products under Investigation by Universities/Institutes, H2 2017 23 Number of Products by Stage and Mechanism of Actions, H2 2017 25 Number of Products by Stage and Route of Administration, H2 2017 27 Number of Products by Stage and Molecule Type, H2 2017 29 Pipeline by Array BioPharma Inc, H2 2017 30 Pipeline by Astellas Pharma Inc, H2 2017 31 Pipeline by AstraZeneca Plc, H2 2017 31 Pipeline by Daiichi Sankyo Co Ltd, H2 2017 32 Pipeline by Dompe Farmaceutici SpA, H2 2017 32 Pipeline by Genzyme Corp, H2 2017 33 Pipeline by Handok Inc, H2 2017 33 Pipeline by Ignyta Inc, H2 2017 34 Pipeline by Loxo Oncology Inc, H2 2017 35 Pipeline by Merck & Co Inc, H2 2017 36 Pipeline by Nerviano Medical Sciences Srl, H2 2017 36 Pipeline by Plexxikon Inc, H2 2017 37 Pipeline by Proximagen Ltd, H2 2017 37 Pipeline by Rottapharm Biotech Srl, H2 2017 38 Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 38 Pipeline by Tiziana Life Sciences Plc, H2 2017 39 Dormant Products, H2 2017 86 Dormant Products, H2 2017 (Contd..1), H2 2017 87 Dormant Products, H2 2017 (Contd..2), H2 2017 88 Discontinued Products, H2 2017 89 Discontinued Products, H2 2017 (Contd..1), H2 2017 90 List of Figures Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Top 10 Indications, H2 2017 12 Number of Products by Mechanism of Actions, H2 2017 24 Number of Products by Stage and Mechanism of Actions, H2 2017 24 Number of Products by Routes of Administration, H2 2017 26 Number of Products by Stage and Routes of Administration, H2 2017 26 Number of Products by Molecule Types, H2 2017 28 Number of Products by Stage and Molecule Types, H2 2017 28

Array BioPharma Inc Astellas Pharma Inc AstraZeneca Plc Daiichi Sankyo Co Ltd Dompe Farmaceutici SpA Genzyme Corp Handok Inc Ignyta Inc Loxo Oncology Inc Merck & Co Inc Nerviano Medical Sciences Srl Plexxikon Inc Proximagen Ltd Rottapharm Biotech Srl Sienna Biopharmaceuticals Inc Tiziana Life Sciences Plc